These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Moore DH Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD001447. PubMed ID: 22419278 [TBL] [Abstract][Full Text] [Related]
9. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460 [TBL] [Abstract][Full Text] [Related]
10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411 [TBL] [Abstract][Full Text] [Related]
11. Drug treatment for spinal muscular atrophy type I. Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF Cochrane Database Syst Rev; 2012 Apr; (4):CD006281. PubMed ID: 22513939 [TBL] [Abstract][Full Text] [Related]
12. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole. Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927 [TBL] [Abstract][Full Text] [Related]
13. Riluzole and ALS therapy. Hugon J Wien Med Wochenschr; 1996; 146(9-10):185-7. PubMed ID: 8873431 [TBL] [Abstract][Full Text] [Related]
14. Drug treatment for spinal muscular atrophy type I. Bosboom W; Vrancken AF; van den Berg LH; Wokke J; Iannaccone ST Cochrane Database Syst Rev; 2009 Jan; (1):CD006281. PubMed ID: 19160274 [TBL] [Abstract][Full Text] [Related]
15. Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). Zoing MC; Burke D; Pamphlett R; Kiernan MC J Clin Neurosci; 2006 Jan; 13(1):78-83. PubMed ID: 16410201 [TBL] [Abstract][Full Text] [Related]
16. Motor neuron disease: systematic reviews of treatment for ALS and SMA. Orrell RW Br Med Bull; 2010; 93():145-59. PubMed ID: 20015852 [TBL] [Abstract][Full Text] [Related]
17. Autosomal recessive proximal spinal muscular atrophy in 101 sibs out of 48 families: clinical picture, influence of gender, and genetic implications. Rudnik-Schöneborn S; Röhrig D; Morgan G; Wirth B; Zerres K Am J Med Genet; 1994 May; 51(1):70-6. PubMed ID: 8030672 [TBL] [Abstract][Full Text] [Related]
18. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Levine TD; Bowser R; Hank N; Saperstein D Amyotroph Lateral Scler; 2010 Dec; 11(6):514-9. PubMed ID: 20839903 [TBL] [Abstract][Full Text] [Related]
19. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC; Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031 [TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Rudnik-Schöneborn S; Berg C; Zerres K; Betzler C; Grimm T; Eggermann T; Eggermann K; Wirth R; Wirth B; Heller R Clin Genet; 2009 Aug; 76(2):168-78. PubMed ID: 19780763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]